Thorough QT study with recommended and supratherapeutic doses of tolterodine (Q79881692)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17339867%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

title

Thorough QT study with recommended and supratherapeutic doses of tolterodine (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17339867%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17339867%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

author name string

Malhotra BK

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17339867%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

Sweeney K

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17339867%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

Anziano R

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17339867%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

Mancuso J

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17339867%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

Wicker P

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17339867%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

publication date

1 March 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17339867%20AND%20SRC:MED&resulttype=core&format=json

Clinical Pharmacology & Therapeutics

26 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17339867%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

volume

81

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17339867%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17339867%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

page(s)

377-385

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17339867%20AND%20SRC:MED&resulttype=core&format=json

Tolterodine--a new bladder-selective antimuscarinic agent

26 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100089

7 January 2021

Efficacy and safety of tolterodine in patients with detrusor instability: a dose-ranging study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100089

7 January 2021

Clinical experiences with tolterodine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100089

7 January 2021

Influence of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamic of tolterodine.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100089

7 January 2021

Ketoconazole inhibits the metabolism of tolterodine in subjects with deficient CYP2D6 activity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100089

7 January 2021

Antimuscarinic potency and bladder selectivity of PNU-200577, a major metabolite of tolterodine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100089

7 January 2021

Multiple dose pharmacokinetics of a new once daily extended release tolterodine formulation versus immediate release tolterodine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100089

7 January 2021

Cardiac ion channel effects of tolterodine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100089

7 January 2021

Safety profile of tolterodine as used in general practice in England: results of prescription-event monitoring

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100089

7 January 2021

Electrocardiographic identification of drug-induced QT prolongation: assessment by different recording and measurement methods.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100089

7 January 2021

Clinical assessment of drug-induced QT prolongation in association with heart rate changes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100089

7 January 2021

Evaluation of vardenafil and sildenafil on cardiac repolarization

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100089

7 January 2021

QT and QTc interval with standard and supratherapeutic doses of darifenacin, a muscarinic M3 selective receptor antagonist for the treatment of overactive bladder

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100089

7 January 2021

Modeling and Interpreting QTc Prolongation in Clinical Pharmacology Studies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100089

7 January 2021

Drug-induced QT dispersion: does it predict the risk of torsade de pointes?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100089

7 January 2021

Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100089

7 January 2021

Rate-corrected QT interval: techniques and limitations

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100089

7 January 2021

Identifiers

DOI

10.1038/SJ.CLPT.6100089

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17339867%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

1 reference